1. Home
  2. CASH vs NRIX Comparison

CASH vs NRIX Comparison

Compare CASH & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pathward Financial Inc.

CASH

Pathward Financial Inc.

HOLD

Current Price

$76.48

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$18.70

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CASH
NRIX
Founded
1954
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CASH
NRIX
Price
$76.48
$18.70
Analyst Decision
Buy
Strong Buy
Analyst Count
2
13
Target Price
$91.00
$29.08
AVG Volume (30 Days)
219.1K
1.5M
Earning Date
01-22-2026
02-12-2026
Dividend Yield
0.27%
N/A
EPS Growth
9.29
N/A
EPS
7.87
N/A
Revenue
$780,120,000.00
$83,687,000.00
Revenue This Year
$10.95
$59.40
Revenue Next Year
$4.75
N/A
P/E Ratio
$9.50
N/A
Revenue Growth
5.66
48.32
52 Week Low
$64.45
$8.18
52 Week High
$86.00
$22.50

Technical Indicators

Market Signals
Indicator
CASH
NRIX
Relative Strength Index (RSI) 61.03 54.89
Support Level $73.08 $17.97
Resistance Level $75.48 $19.55
Average True Range (ATR) 1.67 0.93
MACD 0.14 -0.12
Stochastic Oscillator 95.42 62.29

Price Performance

Historical Comparison
CASH
NRIX

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: